Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler bought 5,500 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were purchased at an average price of $22.00 per share, for a total transaction of $121,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Accelerate Diagnostics, Inc. (NASDAQ AXDX) traded up $0.25 during trading hours on Thursday, hitting $26.30. The stock had a trading volume of 765,700 shares, compared to its average volume of 344,866. Accelerate Diagnostics, Inc. has a twelve month low of $16.75 and a twelve month high of $30.45.

ILLEGAL ACTIVITY WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/insider-buying-accelerate-diagnostics-inc-axdx-director-purchases-121000-00-in-stock/1722234.html.

Several large investors have recently modified their holdings of the company. Legal & General Group Plc lifted its position in shares of Accelerate Diagnostics by 0.3% in the first quarter. Legal & General Group Plc now owns 5,123 shares of the medical research company’s stock valued at $123,000 after acquiring an additional 15 shares in the last quarter. Geneva Advisors LLC lifted its position in shares of Accelerate Diagnostics by 0.5% in the second quarter. Geneva Advisors LLC now owns 48,899 shares of the medical research company’s stock valued at $1,337,000 after acquiring an additional 238 shares in the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Accelerate Diagnostics by 2.2% in the second quarter. Parametric Portfolio Associates LLC now owns 22,966 shares of the medical research company’s stock valued at $628,000 after acquiring an additional 492 shares in the last quarter. Obermeyer Wood Investment Counsel Lllp lifted its position in shares of Accelerate Diagnostics by 0.3% in the second quarter. Obermeyer Wood Investment Counsel Lllp now owns 213,367 shares of the medical research company’s stock valued at $5,836,000 after acquiring an additional 660 shares in the last quarter. Finally, California State Teachers Retirement System lifted its position in shares of Accelerate Diagnostics by 1.5% in the second quarter. California State Teachers Retirement System now owns 46,111 shares of the medical research company’s stock valued at $1,261,000 after acquiring an additional 700 shares in the last quarter. Institutional investors and hedge funds own 45.43% of the company’s stock.

A number of analysts have commented on the company. ValuEngine downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Zacks Investment Research downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Finally, BidaskClub downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Three analysts have rated the stock with a sell rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $33.00.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.